Cargando…
Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database
PURPOSE: Tizanidine, an alpha-adrenergic substance with antinociceptive and antihypertensive effects, is extensively metabolized via cytochrome P450 (CYP) 1A2. Therefore, coadministration with potent CYP1A2 inhibitors, such as ciprofloxacin, is contraindicated. However, both drugs are broadly utiliz...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128801/ https://www.ncbi.nlm.nih.gov/pubmed/33404754 http://dx.doi.org/10.1007/s00228-020-02981-2 |
_version_ | 1783694170954661888 |
---|---|
author | Rudolph, Annette Dahmke, Hendrike Kupferschmidt, Hugo Burden, Andrea Weiler, Stefan |
author_facet | Rudolph, Annette Dahmke, Hendrike Kupferschmidt, Hugo Burden, Andrea Weiler, Stefan |
author_sort | Rudolph, Annette |
collection | PubMed |
description | PURPOSE: Tizanidine, an alpha-adrenergic substance with antinociceptive and antihypertensive effects, is extensively metabolized via cytochrome P450 (CYP) 1A2. Therefore, coadministration with potent CYP1A2 inhibitors, such as ciprofloxacin, is contraindicated. However, both drugs are broadly utilized in various countries. Their concomitant use bears an inherent high risk for clinically significant symptoms, especially in multimorbid patients experiencing polypharmacy. This study aims to investigate the impact of coadministration of tizanidine and ciprofloxacin using real-world pharmacovigilance data and to raise awareness of this potentially underestimated safety issue. METHODS: We conducted a retrospective study including Individual Case Safety Reports (ICSR) registered until March 1, 2017, in the World Health Organization (WHO) global database. Demographic data, drug administration information, the course of the adverse drug reaction (ADR), its severity, and outcomes were analyzed for cases reporting ciprofloxacin comedication. RESULTS: In 91 (2.0%) of the identified 4192 worldwide ICSR on tizanidine, coadministration of ciprofloxacin was reported. Most of the patients were female (n = 59, 64.8%) with a median age of 54 years (range 13–85 years). The countries contributing most reports were the USA (n = 54, 59.3%) and Switzerland (n = 16, 17.6%). ADRs reported most often affected the nervous system and the cardiac function, especially with large tizanidine doses or drugs with CNS and cardiovascular depressant effects. In two cases, a fatal outcome was reported. CONCLUSION: Despite the existing formal contraindication, the concomitant use of tizanidine and ciprofloxacin can be observed in real-world clinical practice. Reactions mainly affected the central nervous and the cardiovascular system resulting in potentially severe adverse effects. The concomitant use of tizanidine and ciprofloxacin should absolutely be avoided. |
format | Online Article Text |
id | pubmed-8128801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-81288012021-05-24 Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database Rudolph, Annette Dahmke, Hendrike Kupferschmidt, Hugo Burden, Andrea Weiler, Stefan Eur J Clin Pharmacol Pharmacoepidemiology and Prescription PURPOSE: Tizanidine, an alpha-adrenergic substance with antinociceptive and antihypertensive effects, is extensively metabolized via cytochrome P450 (CYP) 1A2. Therefore, coadministration with potent CYP1A2 inhibitors, such as ciprofloxacin, is contraindicated. However, both drugs are broadly utilized in various countries. Their concomitant use bears an inherent high risk for clinically significant symptoms, especially in multimorbid patients experiencing polypharmacy. This study aims to investigate the impact of coadministration of tizanidine and ciprofloxacin using real-world pharmacovigilance data and to raise awareness of this potentially underestimated safety issue. METHODS: We conducted a retrospective study including Individual Case Safety Reports (ICSR) registered until March 1, 2017, in the World Health Organization (WHO) global database. Demographic data, drug administration information, the course of the adverse drug reaction (ADR), its severity, and outcomes were analyzed for cases reporting ciprofloxacin comedication. RESULTS: In 91 (2.0%) of the identified 4192 worldwide ICSR on tizanidine, coadministration of ciprofloxacin was reported. Most of the patients were female (n = 59, 64.8%) with a median age of 54 years (range 13–85 years). The countries contributing most reports were the USA (n = 54, 59.3%) and Switzerland (n = 16, 17.6%). ADRs reported most often affected the nervous system and the cardiac function, especially with large tizanidine doses or drugs with CNS and cardiovascular depressant effects. In two cases, a fatal outcome was reported. CONCLUSION: Despite the existing formal contraindication, the concomitant use of tizanidine and ciprofloxacin can be observed in real-world clinical practice. Reactions mainly affected the central nervous and the cardiovascular system resulting in potentially severe adverse effects. The concomitant use of tizanidine and ciprofloxacin should absolutely be avoided. Springer Berlin Heidelberg 2021-01-06 2021 /pmc/articles/PMC8128801/ /pubmed/33404754 http://dx.doi.org/10.1007/s00228-020-02981-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Pharmacoepidemiology and Prescription Rudolph, Annette Dahmke, Hendrike Kupferschmidt, Hugo Burden, Andrea Weiler, Stefan Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database |
title | Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database |
title_full | Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database |
title_fullStr | Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database |
title_full_unstemmed | Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database |
title_short | Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database |
title_sort | coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the who pharmacovigilance database |
topic | Pharmacoepidemiology and Prescription |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128801/ https://www.ncbi.nlm.nih.gov/pubmed/33404754 http://dx.doi.org/10.1007/s00228-020-02981-2 |
work_keys_str_mv | AT rudolphannette coadministrationoftizanidineandciprofloxacinaretrospectiveanalysisofthewhopharmacovigilancedatabase AT dahmkehendrike coadministrationoftizanidineandciprofloxacinaretrospectiveanalysisofthewhopharmacovigilancedatabase AT kupferschmidthugo coadministrationoftizanidineandciprofloxacinaretrospectiveanalysisofthewhopharmacovigilancedatabase AT burdenandrea coadministrationoftizanidineandciprofloxacinaretrospectiveanalysisofthewhopharmacovigilancedatabase AT weilerstefan coadministrationoftizanidineandciprofloxacinaretrospectiveanalysisofthewhopharmacovigilancedatabase |